Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Saniona

11.23 SEK+0.36 %20.11, 17.29
Less than 1K followers

SANION

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+0.36 %
+6.34 %
-10.59 %
-17.49 %
-47.03 %
-34.63 %
+100.49 %
+15.81 %
+186.75 %

Saniona is a biotechnology company focused on developing treatments for neurological and psychiatric diseases. The company is researching new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Saniona was founded in 2011 and is headquartered in Denmark.

Read more
Market cap
1.55B SEK
Turnover
2.9M SEK
Revenue
434.4M
EBIT %
62.39 %
P/E
5.08
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
26.11
2026

Interim report Q3'26

25.2
2027

Annual report '26

All
Research
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release20.11.2026, 08.00

Saniona appoints Carrie Cook as Chief Business Officer

Saniona
Press release19.11.2026, 08.00

Invitation to Saniona Q3 investor call on 26 November 2026

Saniona
Press release17.11.2026, 13.17

Redeye: Saniona: FDA clears SAN2465 for Phase I

Saniona

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release16.11.2026, 08.00

Saniona receives FDA clearance to initiate Phase 1 of SAN2465

Saniona
Press release13.11.2026, 08.00

Saniona receives positive EU orphan drug designation opinion for SAN2668 in CHD2-related neurodevelopmental disorder

Saniona
Press release10.11.2026, 08.00

Saniona sells AstronauTx shareholding for GBP 3.36 million (SEK 44.5 million)

Saniona
Press release06.11.2026, 08.00

Saniona successfully completes Phase 1-enabling work for SAN2668

Saniona
Press release03.11.2026, 08.00

Saniona AB’s Nomination Committee for the Annual General Meeting 2027

Saniona
Regulatory press release02.11.2026, 12.00

Bulletin from the Saniona AB extraordinary shareholders’ meeting on November 2, 2026

Saniona
Press release20.10.2026, 08.00

Saniona submits IND application for SAN2465 for major depressive disorder

Saniona
Press release13.10.2026, 08.00

Saniona announces new preclinical data reinforcing SAN2465’s potential as a rapid-acting antidepressant

Saniona
Press release08.10.2026, 08.00

Saniona to attend and present at several conferences in 2026

Saniona
Regulatory press release07.10.2026, 08.00

Notice of Saniona AB extraordinary shareholders’ meeting

Saniona
Press release24.09.2026, 08.00

Saniona completes toxicology and CMC studies for SAN2465, enabling IND submission by October 2026

Saniona
Press release07.09.2026, 18.01

Redeye: Saniona (Q2 review): With focus into the clinic

Saniona
Press release01.09.2026, 15.20

BioStock: Saniona’s platform has delivered for others – now it delivers for itself

Saniona
Regulatory press release27.08.2026, 08.00

Saniona publishes its interim report for the second quarter of 2026

Saniona
Press release20.08.2026, 08.00

Invitation to Saniona Q2 investor call on 27 August 2026

Saniona
Press release18.08.2026, 09.15

BioStock: Saniona on the equity and milestone upside in the AstronauTx deal

Saniona
Regulatory press release10.08.2026, 08.00

AstronauTx exercises option from Saniona to acquire worldwide rights to neurological disease program under research collaboration

Saniona